SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Biolase, Inc – ‘10-Q’ for 3/31/13 – ‘EX-32.2’

On:  Friday, 5/10/13, at 4:58pm ET   ·   For:  3/31/13   ·   Accession #:  1193125-13-214464   ·   File #:  0-19627

Previous ‘10-Q’:  ‘10-Q’ on 11/9/12 for 9/30/12   ·   Next:  ‘10-Q’ on 8/9/13 for 6/30/13   ·   Latest:  ‘10-Q’ on 11/9/23 for 9/30/23

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/10/13  Biolase, Inc                      10-Q        3/31/13   61:3.9M                                   Donnelley … Solutions/FA

Quarterly Report   —   Form 10-Q   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    313K 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     24K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     24K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     19K 
 5: EX-32.2     Certification -- §906 - SOA'02                      HTML     19K 
40: R1          Document and Entity Information                     HTML     40K 
30: R2          Consolidated Balance Sheets                         HTML    135K 
38: R3          Consolidated Balance Sheets (Parenthetical)         HTML     47K 
42: R4          Consolidated Statements Of Operations And           HTML    102K 
                Comprehensive Loss                                               
55: R5          Consolidated Statements Of Cash Flows               HTML    128K 
32: R6          Basis of Presentation                               HTML     35K 
37: R7          Recent Accounting Pronouncements                    HTML     27K 
27: R8          Stock-Based Awards and Per Share Information        HTML     60K 
19: R9          Inventory                                           HTML     26K 
57: R10         Property, Plant, and Equipment                      HTML     32K 
44: R11         Intangible Assets and Goodwill                      HTML     46K 
43: R12         Accrued Liabilities and Deferred Revenue            HTML     43K 
48: R13         Lines Of Credit and Other Borrowings                HTML     27K 
49: R14         Commitments and Contingencies                       HTML     30K 
47: R15         Segment Information                                 HTML     32K 
50: R16         Concentrations                                      HTML     21K 
39: R17         Income Taxes                                        HTML     30K 
41: R18         Subsequent Events                                   HTML     24K 
46: R19         Accounting Policies (Policies)                      HTML     89K 
61: R20         Stock-Based Awards and Per Share Information        HTML     59K 
                (Tables)                                                         
52: R21         Inventory (Tables)                                  HTML     24K 
34: R22         Property, Plant, and Equipment (Tables)             HTML     30K 
45: R23         Intangible Assets and Goodwill (Tables)             HTML     40K 
36: R24         Accrued Liabilities and Deferred Revenue (Tables)   HTML     48K 
15: R25         Segment Information (Tables)                        HTML     25K 
53: R26         Basis of Presentation - Additional Information      HTML     44K 
                (Detail)                                                         
58: R27         Stock Based Awards and Per Share Information -      HTML     74K 
                Additional Information (Detail)                                  
23: R28         Classification of Compensation Expense Associated   HTML     27K 
                with Share-Based Payments (Detail)                               
22: R29         Assumptions Used in Estimating Fair Value of Stock  HTML     30K 
                Options Granted (Detail)                                         
25: R30         Summary of Option Activity (Detail)                 HTML     71K 
26: R31         Cash Proceeds Along with Fair Value Disclosures     HTML     37K 
                Related to grants Exercises and Vesting Options                  
                (Detail)                                                         
28: R32         Components of Inventory (Detail)                    HTML     31K 
14: R33         Inventory - Additional Information (Detail)         HTML     24K 
51: R34         Summary of Property, Plant, and Equipment (Detail)  HTML     36K 
33: R35         Property, Plant, and Equipment - Additional         HTML     21K 
                Information (Detail)                                             
35: R36         Intangible Assets and Goodwill - Additional         HTML     22K 
                Information (Detail)                                             
17: R37         Intangible Assets Related to Accumulated            HTML     51K 
                Amortization and Goodwill (Detail)                               
60: R38         Components of Accrued Liabilities (Detail)          HTML     43K 
12: R39         Changes In Initial Product Warranty Accrual and     HTML     37K 
                Expenses Under Initial and Extended Warranties                   
                (Detail)                                                         
29: R40         Summary of Deferred Revenue (Detail)                HTML     37K 
54: R41         Lines of Credit and Other Borrowings - Additional   HTML     66K 
                Information (Detail)                                             
16: R42         Commitments and Contingencies - Additional          HTML     37K 
                Information (Detail)                                             
21: R43         Segment Information - Additional Information        HTML     29K 
                (Detail)                                                         
24: R44         Summary of Net Revenue by Geographic Location       HTML     23K 
                (Detail)                                                         
31: R45         Concentrations - Additional Information (Detail)    HTML     29K 
13: R46         Income Taxes - Additional Information (Detail)      HTML     55K 
18: R47         Subsequent Events - Additional Information          HTML     54K 
                (Detail)                                                         
59: XML         IDEA XML File -- Filing Summary                      XML     90K 
20: EXCEL       IDEA Workbook of Financial Reports (.xls)            XLS    425K 
 6: EX-101.INS  XBRL Instance -- biol-20130331                       XML    711K 
 8: EX-101.CAL  XBRL Calculations -- biol-20130331_cal               XML    159K 
 9: EX-101.DEF  XBRL Definitions -- biol-20130331_def                XML    678K 
10: EX-101.LAB  XBRL Labels -- biol-20130331_lab                     XML    991K 
11: EX-101.PRE  XBRL Presentations -- biol-20130331_pre              XML    767K 
 7: EX-101.SCH  XBRL Schema -- biol-20130331                         XSD    144K 
56: ZIP         XBRL Zipped Folder -- 0001193125-13-214464-xbrl      Zip    114K 


‘EX-32.2’   —   Certification — §906 – SOA’02


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



  EX-32.2  

Exhibit 32.2

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of BIOLASE, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2013, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Frederick D. Furry, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(i) the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: May 10, 2013  

/s/ FREDERICK D. FURRY

  Frederick D. Furry
 

Chief Financial Officer

(Principal Financial and Accounting Officer)


Dates Referenced Herein

This ‘10-Q’ Filing    Date    Other Filings
Filed on:5/10/13None on these Dates
For Period end:3/31/13
 List all Filings 
Top
Filing Submission 0001193125-13-214464   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., Apr. 26, 11:14:07.1pm ET